BTIG sets stock target on VYNE with Buy rating on innovation

On Monday, BTIG initiated coverage on VYNE Therapeutics (NASDAQ:VYNE) shares, issuing a Buy rating and setting a price target of $8.00. The firm highlighted the company's innovative work in the development of bromodomain and extra-terminal (BET) inhibitors, particularly for inflammation and immunology (I&I) applications.

VYNE's lead program, VYN201, a topical BET inhibitor, is recognized for its potential as a first-line treatment for non-segmental vitiligo, a condition affecting approximately 1.9 million individuals in the United States, with only around 200,000 currently seeking treatment. The market is expected to grow with the introduction of safer and more effective therapies.

The analyst noted the promising results from the Phase 1b trial of VYN201, which indicated a favorable safety profile and efficacy that could challenge the current standard of care. The ongoing Phase 2b trial, with results anticipated in mid-2025, is testing a higher dose and may show even better efficacy.

BTIG also anticipates positive developments from VYNE's oral BET inhibitor, VYN202, which is moving towards trials for psoriasis and rheumatoid arthritis. The firm's research suggests that BET inhibition might offer efficacy comparable to JAK inhibitors but without the associated safety concerns.

The firm's positive outlook is further supported by the company's financial position, with a current enterprise value of approximately $45 million on a warrant-converted basis and a cash runway extending through the end of 2025. The next catalysts for VYNE are expected to provide significant upside potential for the company's shares.

In other recent news, VYNE Therapeutics reported positive early trial results for its inflammation drug, VYN202. The initial phase of the Phase 1a clinical trial revealed that VYN202 was generally well tolerated across all dose levels and showed dose-dependent exposure in the bloodstream.

Furthermore, the drug has shown inhibitory effects on certain inflammatory biomarkers, suggesting potential therapeutic benefits for conditions such as psoriasis and rheumatoid arthritis. The next phase of the trial, evaluating the drug over a 14-day period, is expected to commence soon.

In financial developments, VYNE reported a second-quarter loss per share of $0.22, slightly higher than the analyst-estimated loss of $0.19. Despite this, TD Cowen and H.C. Wainwright maintained their Buy ratings for the company. The firm also announced it had $78.1 million in cash at the end of the quarter, which is projected to fund operations through 2025.

The company has also been actively progressing with its two primary assets, VYN201 and VYN202. VYNE recently started dosing for the Phase 2b trial for VYN201 in treating vitiligo, and secured a UK patent for its VYN202 program compound. These are among the recent developments at VYNE Therapeutics.

InvestingPro Insights

VYNE Therapeutics' recent market performance and financial metrics offer additional context to BTIG's bullish outlook. According to InvestingPro data, VYNE has shown strong returns over the last month and three months, with price total returns of 21.9% and 45.16% respectively. This recent momentum aligns with BTIG's positive stance on the company's potential.

However, investors should note that VYNE's financials reflect its current stage as a development-stage biopharmaceutical company. The company reported revenue of $0.49 million in the last twelve months, with a significant operating loss of $37.7 million. An InvestingPro Tip highlights that VYNE is not profitable over the last twelve months, which is typical for biotech companies in the research and development phase.

Despite these challenges, VYNE's balance sheet shows some strength. An InvestingPro Tip indicates that the company holds more cash than debt, which supports BTIG's observation about VYNE's cash runway. This financial cushion could be crucial as the company progresses through its clinical trials and awaits potential catalysts.

For investors seeking a more comprehensive analysis, InvestingPro offers 7 additional tips for VYNE Therapeutics, providing a deeper understanding of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.